Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.
At IgMin Research, we bridge the frontiers of Biology, Medicine, and Engineering to foster interdisciplinary innovation. Our expanded scope now embraces a wide spectrum of scientific disciplines, empowering global researchers to explore, contribute, and collaborate through open access.
Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.
IgMin Publications Inc., Suite 102, West Hartford, CT - 06110, USA
We support fostering a collaborative environment where interdisciplinary knowledge is exchanged freely.
Biography
Dr. Sergey S. Galkin is a distinguished researcher and associate professor at the Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia. He is affiliated with the Department of Neurology, Neurosurgery, and Medical Genetics at RNRMU, which operates under the Ministry of Health of the Russian Federation. His research primarily focuses on molecular biology, biochemistry, and genomics, with a particular emphasis on ischemic stroke and platelet aggregation.
Dr. Galkin has co-authored several significant studies, including a notable publication titled “The Model for Clinical, Laboratory, and Genetic Prediction of Recurrent Ischemic Stroke against the Background of Laboratory Aspirin Resistance using Machine Learning,” published in the journal Biomedicines. This study aimed to determine the incidence of laboratory aspirin resistance and explore the associations of genetic markers and clinical parameters in patients with
non-cardioembolic ischemic stroke. The research utilized machine learning methods to assess the prognosis of recurrent ischemic strokes, analyzing clinical and laboratory data from 296 patients treated at City Clinical Hospital No. 1 named after N.I. Pirogov.
In addition to his academic contributions, Dr. Galkin has collaborated with the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, further strengthening the interdisciplinary nature of his research. His work exemplifies the integration of clinical expertise with advanced molecular techniques to address complex neurological conditions.
Research Interest
Dr. Sergey S. Galkin's research interests primarily lie in the fields of molecular biology, neurology, and genomics, with a particular focus on ischemic stroke and platelet aggregation. His work investigates the genetic, clinical, and laboratory factors influencing stroke outcomes, especially recurrent ischemic stroke. By integrating molecular biology with clinical practices, Dr. Galkin seeks to improve diagnostic and prognostic methods for stroke patients. A significant portion of his research explores aspirin resistance and its genetic underpinnings, utilizing advanced techniques such as machine learning for clinical prediction models. He has co-authored studies that aim to enhance personalized medicine approaches for stroke treatment, specifically by identifying biomarkers that could predict recurrence risks. Additionally, Dr. Galkin collaborates with various research institutions, including the Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, aiming to bridge the gap between laboratory findings and clinical applications for better stroke management and prevention strategies.
Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.
byAnastasia V Anisimova, Sergey S Galkin, Anastasia S Gunchenko, Tatyana V Nasedkina and Igor V Vorobiev
The aim of the study was to determine the incidence of laboratory aspirin resistance; and to study the associations of genetic markers and clinical and laboratory parameters (including parameters of the platelet hemostasis) in patients with non-cardioembolic ischemic stroke using machine learning methods to assess the prognosis of recurrent ischemic strokes. Clinical and laboratory data (including induced platelet aggregation) were analyzed from 296 patients with ischemic stroke who were treated in the stroke center of City Clinical Hospital No.... 1 named after. N.I. Pirogov. The frequencies of polymorphic variants of the ITGB3, GPIba, TBXA2R, ITGA2, PLA2G7, HMOX1, PTGS1, PTGS2, ADRA2A, ABCB1, PEAR1 genes and intergenic region 9p21.3) in patients with non-cardioembolic ischemic stroke, which were identified using hydrogel biochip technology, were determined. Using the developed machine learning model, additional clinical and genetic factors influencing the development of laboratory aspirin resistance and recurrent ischemic stroke were studied. In the future, the identified factors can be used for differentiated prevention of recurrent ischemic strokes.
